Quanterix logo

QuanterixNASDAQ: QTRX

Profile

Sector:

Healthcare

Country:

United States

IPO:

07 December 2017

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$515.43 M
-75%vs. 3y high
65%vs. sector
-vs. 3y high
-vs. sector
-66%vs. 3y high
50%vs. sector
-81%vs. 3y high
54%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:44 GMT
$13.43+$0.21(+1.63%)

Dividend

No data over the past 3 years
$34.13 M$34.17 M
$34.13 M-$9.47 M

Analysts recommendations

Institutional Ownership

QTRX Latest News

New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer's Disease Diagnostic Information
businesswire.com28 October 2024 Sentiment: POSITIVE

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer's Disease (AD) in a broader range of patients. Recent Alzheimer's Association criteria for diagnosing Alzheimer's recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this app.

Quanterix Corporation: Still Struggling To Gain Traction
seekingalpha.com26 August 2024 Sentiment: POSITIVE

Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it.  Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection.

Jeffrey Elliott Appointed to Quanterix's Board of Directors
businesswire.com19 August 2024 Sentiment: POSITIVE

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating.

Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.

Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade
Zacks Investment Research15 May 2024 Sentiment: POSITIVE

The average price target suggests a potential increase of 67.7% for Quanterix (QTRX). Although studies show that this metric may not always be reliable, an increase in earnings estimates could indicate a positive outlook for the stock in the short term.

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Zacks Investment Research06 March 2024 Sentiment: POSITIVE

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research29 February 2024 Sentiment: NEUTRAL

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
Zacks Investment Research27 February 2024 Sentiment: POSITIVE

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
Business Wire26 February 2024 Sentiment: NEUTRAL

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.

Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
Zacks Investment Research04 December 2023 Sentiment: POSITIVE

Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • 1(current)

What type of business is Quanterix?

Quanterix Corporation develops an ultra-sensitive platform for digital immunoassay and tools for medical-biological research and diagnostics. The company offers a single molecule platform (Simoa) that uses single molecule measurements to detect protein biomarkers. The company also focuses on implementing and developing new treatment and diagnostic methods, making medical services easier for early detection, monitoring, prognosis, and ultimately disease prevention. Simoa specializes in research and clinical trials and significantly advances the enzyme-linked immunosorbent assay (ELISA) technology, providing unprecedented sensitivity in protein detection. Quanterix Corporation was founded in 2007, with its headquarters located in Billerica, Massachusetts.

What sector is Quanterix in?

Quanterix is in the Healthcare sector

What industry is Quanterix in?

Quanterix is in the Medical Devices industry

What country is Quanterix from?

Quanterix is headquartered in United States

When did Quanterix go public?

Quanterix initial public offering (IPO) was on 07 December 2017

What is Quanterix website?

https://www.quanterix.com

Is Quanterix in the S&P 500?

No, Quanterix is not included in the S&P 500 index

Is Quanterix in the NASDAQ 100?

No, Quanterix is not included in the NASDAQ 100 index

Is Quanterix in the Dow Jones?

No, Quanterix is not included in the Dow Jones index

When was Quanterix the previous earnings report?

No data

When does Quanterix earnings report?

The next expected earnings date for Quanterix is 06 November 2024